Related Experiment Videos
[Accelerated streptokinase dose regimens for coronary thrombolysis]
Forty patients entering our hospital up to 12 hours (5.1 +/- 2.8 hours) after the onset of definite acute myocardial infarction were treated with accelerated streptokinase dose regimens (1.5 million U/30 min) intravenously. The reperfusion rate of infarct-related arteries determined by clinical evidence of reperfusion was 77.5% (31/40). There was significant difference in reperfusion rates: 89.3% (25/28) among patients within 6 hours versus 50% (6/12) among patients within 6-12 hours after the onset of chest pain. Five cases (12.5%) experienced mild bleeding complications. One patient had chill. Three patients (7.5%) had hypotension (BP < or = 10.7/6.67 kPa, 1 kPa = 7.5 mmHg). The 5 week mortality was 2.5% (1/40). In conclusion, intravenous accelerated streptokinase dose regimen for coronary thrombolysis seems to improve reperfusion rate markedly without increasing adverse events such as allergic reactions, severe bleeding and hypotension.
Forty patients entering our hospital up to 12 hours (5.1 +/- 2.8 hours) after the onset of definite acute myocardial infarction were treated with accelerated streptokinase dose regimens (1.5 million U/30 min) intravenously. The reperfusion rate of infarct-related arteries determined by clinical evidence of reperfusion was 77.5% (31/40). There was significant difference in reperfusion rates: 89.3% (25/28) among patients within 6 hours versus 50% (6/12) among patients within 6-12 hours after the onset of chest pain. Five cases (12.5%) experienced mild bleeding complications. One patient had chill. Three patients (7.5%) had hypotension (BP < or = 10.7/6.67 kPa, 1 kPa = 7.5 mmHg). The 5 week mortality was 2.5% (1/40). In conclusion, intravenous accelerated streptokinase dose regimen for coronary thrombolysis seems to improve reperfusion rate markedly without increasing adverse events such as allergic reactions, severe bleeding and hypotension.